Camargo Priscila Goes, Bortoleti Bruna Taciane da Silva, Fabris Marcieli, Gonçalves Manoela Daiele, Tomiotto-Pellissier Fernanda, Costa Idessania Nazareth, Conchon-Costa Ivete, Lima Camilo Henrique da Silva, Pavanelli Wander Rogério, Bispo Marcelle de Lima Ferreira, Macedo Fernando
Departamento de Química, Centro de Ciências Exatas, Universidade Estadual de Londrina, Londrina, Brazil.
Programa de Pós Graduação em Biociências e Biotecnologia, Instituto Carlos Chagas, Curitiba, Brazil.
J Biomol Struct Dyn. 2022 Apr;40(7):3213-3222. doi: 10.1080/07391102.2020.1845979. Epub 2020 Nov 13.
Leishmaniasis is a neglected tropical disease caused by protozoa of the genus . The first-line treatment of this disease is still based on pentavalent antimonial drugs that have a high toxicity profile, which could induce parasitic resistance. Therefore, there is a critical need to discover more effective and selective novel anti-leishmanial agents. In this context, thiohydantoins are a versatile class of substances due to their simple synthesis and several biological activities. In this work, thiohydantoins - were evaluated for antileishmania activity. Among them, four derivatives (, , and ) showed promising IC values around 10 µM against promastigotes forms of and low cytotoxicity profile for peritoneal macrophages cells. Besides, these compounds induce oxidative stress through an increase in ROS production and the labeling of annexin-V and propidium iodide, indicating that promastigotes were undergoing a late apoptosis-like process. Additionally, molecular consensual docking analysis was carried out against two important targets to : arginase and trypanothione reductase enzymes. Docking results suggest that thiohydantoin ring could be a pharmacophoric group due to its binding affinity by hydrogens bond interactions with important amino acid residues at the active site of both enzymes. These results demonstrate that compounds , , and may are promising in future advance studies.Communicated by Ramaswamy H. Sarma.
利什曼病是一种由利什曼原虫属原生动物引起的被忽视的热带疾病。该疾病的一线治疗仍然基于毒性较高的五价锑药物,这可能会诱导寄生虫产生耐药性。因此,迫切需要发现更有效、更具选择性的新型抗利什曼原虫药物。在这种背景下,硫代乙内酰脲因其合成简单且具有多种生物活性而成为一类用途广泛的物质。在这项工作中,对硫代乙内酰脲进行了抗利什曼原虫活性评估。其中,四种衍生物(、、和)对杜氏利什曼原虫前鞭毛体形式显示出约10 µM的有前景的半数抑制浓度(IC值),并且对腹膜巨噬细胞的细胞毒性较低。此外,这些化合物通过增加活性氧(ROS)的产生以及膜联蛋白V和碘化丙啶的标记来诱导氧化应激,表明前鞭毛体正在经历类似晚期凋亡的过程。此外,针对杜氏利什曼原虫的两个重要靶点:精氨酸酶和锥虫硫醇还原酶进行了分子共识对接分析。对接结果表明,硫代乙内酰脲环可能是一个药效基团,因为它通过氢键相互作用与两种酶活性位点的重要氨基酸残基具有结合亲和力。这些结果表明,化合物、、和在未来的进一步研究中可能具有前景。由拉马斯瓦米·H·萨尔马传达。